Literature DB >> 9551363

Tumor vaccines--a reality at last?

I Hellström1, K E Hellström.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9551363

Source DB:  PubMed          Journal:  J Immunother        ISSN： 1524-9557            Impact factor:   4.456


× No keyword cloud information.
  4 in total

1.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

Authors:  D B Chappell; T Z Zaks; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

2.  Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.

Authors:  W W Leitner; H Ying; D A Driver; T W Dubensky; N P Restifo
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

3.  Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.

Authors:  K R Irvine; M R Parkhurst; E P Shulman; J P Tupesis; M Custer; C E Touloukian; P F Robbins; A G Yafal; P Greenhalgh; R P Sutmuller; R Offringa; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

Review 4.  Therapeutic vaccination with tumor cells that engage CD137.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Mol Med (Berl)       Date:  2003-02-08       Impact factor: 4.599
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.